PDL BioPharma, Inc. (NASDAQ:PDLI) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 18,146,418 shares, an increase of 13.8% from the August 15th total of 15,943,830 shares. Approximately 12.1% of the company’s stock are sold short. Based on an average trading volume of 1,891,101 shares, the short-interest ratio is currently 9.6 days.

PDL BioPharma (NASDAQ:PDLI) opened at 3.31 on Tuesday. The firm has a 50-day moving average of $2.84 and a 200 day moving average of $2.43. PDL BioPharma has a one year low of $1.93 and a one year high of $3.77. The stock has a market capitalization of $510.00 million, a PE ratio of 7.61 and a beta of 0.49.

PDL BioPharma (NASDAQ:PDLI) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.17. PDL BioPharma had a net margin of 23.03% and a return on equity of 9.07%. The company had revenue of $143.80 million for the quarter, compared to analysts’ expectations of $56.30 million. During the same period in the prior year, the business earned $0.09 EPS. The firm’s quarterly revenue was up 584.8% on a year-over-year basis. On average, equities research analysts anticipate that PDL BioPharma will post $0.61 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on PDLI shares. ValuEngine cut shares of PDL BioPharma from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub cut shares of PDL BioPharma from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 11th. Piper Jaffray Companies reissued a “buy” rating and set a $4.00 price target on shares of PDL BioPharma in a research report on Thursday, August 10th. Finally, Zacks Investment Research raised shares of PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $3.50.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in PDL BioPharma by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 14,180,118 shares of the biotechnology company’s stock worth $32,188,000 after acquiring an additional 827,830 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in PDL BioPharma by 30.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 7,428,030 shares of the biotechnology company’s stock worth $18,348,000 after acquiring an additional 1,744,380 shares in the last quarter. State Street Corp grew its holdings in PDL BioPharma by 14.4% during the 2nd quarter. State Street Corp now owns 5,042,207 shares of the biotechnology company’s stock worth $12,457,000 after acquiring an additional 632,995 shares in the last quarter. Mackenzie Financial Corp grew its holdings in PDL BioPharma by 2.8% during the 1st quarter. Mackenzie Financial Corp now owns 4,818,609 shares of the biotechnology company’s stock worth $10,938,000 after acquiring an additional 130,784 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in PDL BioPharma by 22.0% during the 1st quarter. AQR Capital Management LLC now owns 4,546,501 shares of the biotechnology company’s stock worth $10,321,000 after acquiring an additional 820,481 shares in the last quarter. Institutional investors own 83.35% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/19/pdl-biopharma-inc-pdli-short-interest-update.html.

About PDL BioPharma

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Receive News & Stock Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related stocks with our FREE daily email newsletter.